These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

767 related items for PubMed ID: 19466975

  • 1. Angiogenesis and vascular endothelial growth factor-/receptor expression in myeloproliferative neoplasms: correlation with clinical parameters and JAK2-V617F mutational status.
    Medinger M, Skoda R, Gratwohl A, Theocharides A, Buser A, Heim D, Dirnhofer S, Tichelli A, Tzankov A.
    Br J Haematol; 2009 Jul; 146(2):150-7. PubMed ID: 19466975
    [Abstract] [Full Text] [Related]

  • 2. Bone marrow microvessel density and plasma angiogenic factors in myeloproliferative neoplasms: clinicopathological and molecular correlations.
    Lekovic D, Gotic M, Skoda R, Beleslin-Cokic B, Milic N, Mitrovic-Ajtic O, Nienhold R, Sefer D, Suboticki T, Buac M, Markovic D, Diklic M, Cokic VP.
    Ann Hematol; 2017 Mar; 96(3):393-404. PubMed ID: 27924369
    [Abstract] [Full Text] [Related]

  • 3. Bone marrow microvessel density in chronic myeloproliferative disorders: a study of 115 patients with clinicopathological and molecular correlations.
    Boveri E, Passamonti F, Rumi E, Pietra D, Elena C, Arcaini L, Pascutto C, Castello A, Cazzola M, Magrini U, Lazzarino M.
    Br J Haematol; 2008 Jan; 140(2):162-8. PubMed ID: 18028479
    [Abstract] [Full Text] [Related]

  • 4. JAK2(V617F) allele burden discriminates essential thrombocythemia from a subset of prefibrotic-stage primary myelofibrosis.
    Hussein K, Bock O, Theophile K, von Neuhoff N, Buhr T, Schlué J, Büsche G, Kreipe H.
    Exp Hematol; 2009 Oct; 37(10):1186-1193.e7. PubMed ID: 19616600
    [Abstract] [Full Text] [Related]

  • 5. Identification of oncostatin M as a JAK2 V617F-dependent amplifier of cytokine production and bone marrow remodeling in myeloproliferative neoplasms.
    Hoermann G, Cerny-Reiterer S, Herrmann H, Blatt K, Bilban M, Gisslinger H, Gisslinger B, Müllauer L, Kralovics R, Mannhalter C, Valent P, Mayerhofer M.
    FASEB J; 2012 Feb; 26(2):894-906. PubMed ID: 22051730
    [Abstract] [Full Text] [Related]

  • 6. Dkk3 levels in patients with myeloproliferative neoplasms.
    Medinger M, Muesser P, Girsberger S, Skoda R, Tzankov A, Buser A, Passweg J, Tsakiris DΑ.
    Thromb Res; 2014 Feb; 133(2):218-21. PubMed ID: 24309205
    [Abstract] [Full Text] [Related]

  • 7. Bone marrow phospho-STAT5 expression in non-CML chronic myeloproliferative disorders correlates with JAK2 V617F mutation and provides evidence of in vivo JAK2 activation.
    Aboudola S, Murugesan G, Szpurka H, Ramsingh G, Zhao X, Prescott N, Tubbs RR, Maciejewski JP, Hsi ED.
    Am J Surg Pathol; 2007 Feb; 31(2):233-9. PubMed ID: 17255768
    [Abstract] [Full Text] [Related]

  • 8. The 2001 World Health Organization and updated European clinical and pathological criteria for the diagnosis, classification, and staging of the Philadelphia chromosome-negative chronic myeloproliferative disorders.
    Michiels JJ, De Raeve H, Berneman Z, Van Bockstaele D, Hebeda K, Lam K, Schroyens W.
    Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):307-40. PubMed ID: 16810609
    [Abstract] [Full Text] [Related]

  • 9. The JAK2 V617F allele burden in essential thrombocythemia, polycythemia vera and primary myelofibrosis--impact on disease phenotype.
    Larsen TS, Pallisgaard N, Møller MB, Hasselbalch HC.
    Eur J Haematol; 2007 Dec; 79(6):508-15. PubMed ID: 17961178
    [Abstract] [Full Text] [Related]

  • 10. Changing concepts of diagnostic criteria of myeloproliferative disorders and the molecular etiology and classification of myeloproliferative neoplasms: from Dameshek 1950 to Vainchenker 2005 and beyond.
    Michiels JJ, Berneman Z, Schroyens W, De Raeve H.
    Acta Haematol; 2015 Dec; 133(1):36-51. PubMed ID: 25116092
    [Abstract] [Full Text] [Related]

  • 11. The G allele of the JAK2 rs10974944 SNP, part of JAK2 46/1 haplotype, is strongly associated with JAK2 V617F-positive myeloproliferative neoplasms.
    Trifa AP, Cucuianu A, Petrov L, Urian L, Militaru MS, Dima D, Pop IV, Popp RA.
    Ann Hematol; 2010 Oct; 89(10):979-83. PubMed ID: 20422415
    [Abstract] [Full Text] [Related]

  • 12. Concomitant BCR-ABL1 translocation and JAK2(V617F) mutation in three patients with myeloproliferative neoplasms.
    Hummel JM, Kletecka MC, Sanks JK, Chiselite MD, Roulston D, Smith LB, Czuchlewski DR, Elenitoba-Johnson KS, Lim MS.
    Diagn Mol Pathol; 2012 Sep; 21(3):176-83. PubMed ID: 22847163
    [Abstract] [Full Text] [Related]

  • 13. Frequent detection of the JAK2 V617F mutation in bone marrow core biopsy specimens from chronic myeloproliferative disorders using the TaqMan polymerase chain reaction single nucleotide polymorphism genotyping assay: a retrospective study with pathologic correlations.
    Bousquet M, Le Guellec S, Quelen C, Rigal-Huguet F, Delsol G, Brousset P.
    Hum Pathol; 2006 Nov; 37(11):1458-64. PubMed ID: 16949922
    [Abstract] [Full Text] [Related]

  • 14. Molecular characterization of Ph-negative myeloproliferative neoplasms in Ukraine.
    Mishcheniuk OY, Kostukevich OM, Dmytrenko IV, Sholoyko VV, Prokopenko IM, Martina ZV, Pilipenko GV, Klymenko SV.
    Exp Oncol; 2013 Sep; 35(3):202-6. PubMed ID: 24084459
    [Abstract] [Full Text] [Related]

  • 15. JAK2-v617F mutation is associated with clinical and laboratory features of myeloproliferative neoplasms.
    Duletić AN, Dekanić A, Hadzisejdić I, Kusen I, Matusan-Ilijas K, Grohovac D, Grahovac B, Jonjić N.
    Coll Antropol; 2012 Sep; 36(3):859-65. PubMed ID: 23213945
    [Abstract] [Full Text] [Related]

  • 16. The JAK2 V617F mutational status and allele burden may be related with the risk of venous thromboembolic events in patients with Philadelphia-negative myeloproliferative neoplasms.
    Borowczyk M, Wojtaszewska M, Lewandowski K, Gil L, Lewandowska M, Lehmann-Kopydłowska A, Kroll-Balcerzak R, Balcerzak A, Iwoła M, Michalak M, Komarnicki M.
    Thromb Res; 2015 Feb; 135(2):272-80. PubMed ID: 25559461
    [Abstract] [Full Text] [Related]

  • 17. Angiogenesis in JAK2 V617F positive myeloproliferative neoplasms and ruxolitinib decrease VEGF, HIF-1 enesis in JAK2 V617F positive cells.
    Cheng Z, Fu J, Liu G, Zhang L, Xu Q, Wang SY.
    Leuk Lymphoma; 2018 Jan; 59(1):196-203. PubMed ID: 28554272
    [Abstract] [Full Text] [Related]

  • 18. [Myeloproliferative diseases caused by JAK2 mutation].
    Nagata K, Shimoda K.
    Rinsho Byori; 2009 Apr; 57(4):357-64. PubMed ID: 19489438
    [Abstract] [Full Text] [Related]

  • 19. Correlations between Janus kinase 2 V617F allele burdens and clinicohematologic parameters in myeloproliferative neoplasms.
    Ha JS, Kim YK, Jung SI, Jung HR, Chung IS.
    Ann Lab Med; 2012 Nov; 32(6):385-91. PubMed ID: 23130336
    [Abstract] [Full Text] [Related]

  • 20. The analysis of JAK2 and MPL mutations and JAK2 single nucleotide polymorphisms in MPN patients by MassARRAY assay.
    Zhang SJ, Qiu HX, Li JY, Shi JY, Xu W.
    Int J Lab Hematol; 2010 Aug 01; 32(4):381-6. PubMed ID: 20331763
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 39.